Ivacaftor | Page 3 | European Cystic Fibrosis Society (ECFS)

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Accumulation and persistence of Ivacaftor in airway epithelia with prolonged treatment

Ivacaftor in Cystic Fibrosis With Residual Function: Lung Function Results From an N-of-1 Study

GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis.

Use is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis

An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).

GLPG1837, a CFTR potentiator, in p.Gly551Asp (G551D)-CF patients: An open-label, single-arm, phase 2a study (SAPHIRA1)

first
previous
1
2
3
4
5
next
last